OncoCyte Corp
NASDAQ:OCX

Watchlist Manager
OncoCyte Corp Logo
OncoCyte Corp
NASDAQ:OCX
Watchlist
Price: 2.21 USD 0.91%
Market Cap: 37.2m USD
Have any thoughts about
OncoCyte Corp?
Write Note

OncoCyte Corp
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

OncoCyte Corp
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
OncoCyte Corp
NASDAQ:OCX
Revenue
$709k
CAGR 3-Years
-46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

OncoCyte Corp
Glance View

Market Cap
37.2m USD
Industry
Biotechnology

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 110 full-time employees. The company went IPO on 2015-12-30. The firm is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.

OCX Intrinsic Value
2.67 USD
Undervaluation 17%
Intrinsic Value
Price

See Also

What is OncoCyte Corp's Revenue?
Revenue
709k USD

Based on the financial report for Sep 30, 2024, OncoCyte Corp's Revenue amounts to 709k USD.

What is OncoCyte Corp's Revenue growth rate?
Revenue CAGR 3Y
-46%

Over the last year, the Revenue growth was -51%. The average annual Revenue growth rates for OncoCyte Corp have been -46% over the past three years .

Back to Top